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AbstrAct
Objectives recent studies suggest that implementation 
of the 2010 american college of rheumatology (acr)/
european league against rheumatism (eUlar) 
classification criteria for rheumatoid arthritis (ra) leads 
to higher inflammatory activity in seronegative compared 
with seropositive patients at time of diagnosis. Our aim 
was to compare the disease course in seronegative and 
seropositive patients classified according to the 2010 
criteria.
Methods DMarD-naïve patients with ra fulfilling the 
2010 criteria were included in the treat-to-target arctic 
trial and followed for 24 months. We stratified patients 
as seropositive (rheumatoid factor (rF)+, anticitrullinated 
protein antibodies (acPa)+ or both) or seronegative (rF– 
and acPa–) and compared disease activity, radiographic 
progression, treatment response and remission rates 
across groups.
Results 230 patients were included with mean (SD) age 
51.4 (13.7) years, and 61% were female. 34 patients 
(15%) were seronegative. at 24  months, disease activity 
measures, radiographic progression and remission rates 
were similar between groups, despite more inflammatory 
activity in seronegative patients at baseline. treatment 
response was slower in seronegative compared with 
seropositive patients. the groups received similar 
treatment.
Conclusion Our findings suggest that among patients 
with ra classified according to the 2010 acr/eUlar 
criteria, seronegative patients respond well to modern 
treatment strategies. However, treatment response 
was somewhat slower in seronegative patients and 
radiographic progression was similar in seronegative and 
seropositive patients. Our results indicate that seronegative 
ra is not a mild form of the disease and requires intensive 
treat-to-target therapy similar to treatment of seropositive 
ra.
InTROduCTIOn
Rheumatoid arthritis (RA) is an autoim-
mune, potentially disabling joint disease.1 
RA is currently classified as seropositive 
or seronegative based on the presence 
or absence of rheumatoid factor (RF) 
and anticitrullinated protein antibodies 
Key messages
What is already known about this subject?
 ► Seronegative rheumatoid arthritis (ra) has been 
considered to represent a less severe disease sub-
set than seropositive ra, with less radiographic 
damage.
 ► recent studies indicate that the implementation of 
the 2010 classification criteria for ra, which put 
strong emphasis on serological status, leads to high-
er inflammatory activity in seronegative compared 
with seropositive patients at time of diagnosis.
What does this study add?
 ► Disease activity, remission rates and radiographic 
progression were similar in patients with seroneg-
ative and seropositive ra after 2 years of follow-up.
 ► treatment response was slower in seronegative 
than in seropositive patients, although all patients 
were treated according to the same algorithm.
How might this impact on clinical practice?
 ► these results indicate that patients now classified 
as seronegative ra might have a more serious dis-
ease than the historic perception of this subgroup 
and require intensive therapy similar to treatment of 
seropositive ra.
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(ACPA), and serological status has become important 
in diagnosis, prognostication and treatment decisions. 
Seronegative RA has been considered to represent a 
less severe disease subset than seropositive RA, with 
less radiographic damage.2–6 It has been suggested that 
seronegative patients should be treated less aggressively 
than seropositive patients, which is also reflected in the 
2016 update of the European League Against Rheuma-
tism (EULAR) treatment recommendations.7 8
Implementation of the 2010 American College of 
Rheumatology (ACR)/EULAR classification criteria 
for RA redefined the patient population, including the 
classification of seronegative patients.9 In our recently 
published study of disease-modifying antirheumatic 
drug (DMARD)-naïve patients with early RA fulfilling 
the new classification criteria, we found that seronega-
tive patients had markedly higher inflammatory activity 
at the time of diagnosis compared with seropositive 
patients.10 Based on follow-up data in this cohort, we 
aimed to examine the disease course of seronegative 
patients with early RA fulfilling the 2010 ACR/EULAR 
criteria compared with seropositive patients.
MeTHOds
Patients and study design
Patients with RA fulfilling the 2010 ACR/EULAR clas-
sification criteria were included in the ARCTIC trial 
( ClinicalTrials. gov identifier NCT01205854).11 All 
patients had symptom duration less than 2 years and 
were DMARD naïve with indication for DMARD treat-
ment. We stratified the patients as seropositive (RF+ 
(IgM or IgA), ACPA+ or both) or seronegative (both 
RF– and ACPA–). Patients were randomised 1:1 to 
a treat-to-target strategy with or without ultrasound 
examinations to guide treatment decisions and joint 
injections during follow-up. The same DMARD escala-
tion algorithm was applied in both arms, and inflamed 
joints were treated with intra-articular glucocorticoids 
(triamcinolone hexacetonide). Patients were assessed 
at 13 visits within 24 months. Data from the two strategy 
arms were pooled and analysed together for the 
current study, as clinical and radiographic outcomes 
were similar in the two strategy arms after 2 years.11 The 
study was approved by the regional ethics committee, 
and all patients provided written informed consent.
data collection
The data collection included demographic data, eryth-
rocyte sedimentation rate (mm/hour), C reactive 
protein (mg/L), Ritchie Articular Index, 44 swollen 
joint count (SJC), the patient’s and physician’s global 
assessment of disease activity on 0–100 mm visual 
analogue scales, patient-reported outcome measures 
and radiographs of hands and feet which were scored 
according to the van der Heijde-modified Sharp score 
by two independent readers blinded for patient identity 
and clinical information. The Disease Activity Score 
(DAS) was calculated.12
Ultrasound examinations were performed by trained 
rheumatologists according to a validated 0–3 semi-
quantitative scoring system for grey scale and power 
Doppler.13 Thirty-two joints were included, giving 
ranges from 0 to 96 for grey scale and power Doppler.
Sera were collected in a biobank, and RF and ACPA 
were analysed at the same laboratory by enzyme-linked 
immunosorbent assay ELISA and fluorescence enzyme 
immunoassay, respectively. A positive test was defined 
as any value ≥10 IU/mL for ACPA and ≥25 IU/mL for 
RF.
statistical analyses
Continuous variables are presented as means (SD) or 
medians (25th–75th percentile) according to distribu-
tion. Dichotomous variables are presented as frequen-
cies and percentages. At baseline and 24 month 
follow-up, measures of disease activity were compared 
across groups using independent samples t-test, Mann-
Whitney U test or χ² test as appropriate. We also 
compared the change from baseline in these measures 
between groups. Measures of disease activity at baseline 
and 24-month follow-up were also compared between 
seronegative patients and subgroups of seropositive 
patients (single ACPA+, single RF+ and double-positive 
patients).
Radiographic progression, DAS, SJC44 and ultrasound 
scores over time were compared between seronegative 
and seropositive patients by linear mixed-effects models 
with random intercept for patient in order to account 
for within-patient dependencies. We used robust vari-
ance estimates for ultrasound scores and radiographic 
progression due to skewed distributions. Finally, we 
compared response and remission rates across serology 
status at 3, 6, 12 and 24 months using χ² tests. We also 
assessed treatment response in logistic regression 
models with EULAR good/moderate response at 3 and 
6 months as dependent variables and serology status 
(seronegative/seropositive) baseline SJC44, baseline 
DAS, baseline Ritchie articular index, sex and age as 
independent variables. We performed the same anal-
yses with ACR 50 response at 3 and 6 months as depen-
dent variables.
Statistical tests were two-sided and p<0.05 were consid-
ered statistically significant. Three seronegative and 23 
seropositive patients did not attend the 24 month visit, 
with missing values imputed as described elsewhere.11 
Statistical analyses were performed using Stata 14.
ResulTs
Patients
A total of 238 patients were initially included in the 
ARCTIC trial; of these, 230 attended follow-up visits 
and were thus included in the current study; 34 
patients (15%) were seronegative. In the seronegative/
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seropositive groups, mean (SD) age was 55.4 (15.7)/50.8 
(13.2) years (p=0.07), mean (SD) disease duration was 
7.7 (6.8)/7.0 (5.1) months (p=0.46) and 56%/62% 
were women (p=0.48).
disease severity
At baseline, measures of disease activity were higher 
in seronegative compared with seropositive patients.10 
Seronegative patients had a significantly greater reduc-
tion in disease activity measures (DAS, number of 
swollen joints, physician global and ultrasonography 
scores) resulting in no differences between the groups 
at 24-month follow-up. There was a trend towards more 
radiographic damage in seronegative compared with 
seropositive patients, both at baseline and 24 months 
(table 1).
Measures of disease activity and severity at baseline 
and 24-month follow-up were also compared between 
seronegative patients and subgroups of seropositive 
patients (single ACPA+, single RF+ and double-positive 
patients). These analyses did not substantially change 
the results. At baseline, RF positive (ACPA nega-
tive) and seronegative (both ACPA and RF negative) 
patients had similar levels of inflammatory activity, 
however, the low number of patients in this subgroup 
makes interpretations difficult (online supplementary 
table 1).
During the first 6 months following DMARD initia-
tion, the number of swollen joints and DAS were higher 
in seronegative compared with seropositive patients. 
From month six, they were similar across groups 
(figure 1A,B). Ultrasound scores were not statistically 
significantly different between groups after 1 and 2 
years (figure 1C,D). Radiographic progression was 
similar between the groups (figure 1E,F).
Response and remission rates
Three months after treatment start, response and 
remission rates were lower in seronegative patients, 
and 6% of seronegative patients (2/34) were in ACR/
EULAR Boolean remission compared with 30% of sero-
positive patients (58/196) (p=0.004). From 6 months 
onwards, response and remission rates were similar 
between groups. After 6 months of follow-up, 32% of 
seronegative (11/34) and 35% of seropositive patients 
(69/196) were in ACR/EULAR Boolean remission 
(p=0.75) (table 2). Analyses adjusted for age, gender, 
baseline DAS, baseline SJC44 and baseline Ritchie 
articular index showed that seropositivity was associ-
ated with achieving treatment response at 3 months, 
both for ACR 50 response (OR 3.8 (1.5 to 9.8)) and 
EULAR good/moderate response (OR 3.9 (1.4 11.2)). 
Serology status did not predict treatment response at 6 
months. Higher baseline DAS was associated with treat-
ment response at 6 months, but not at 3 months (data 
not shown).
Treatment
Treatment was similar across groups during the study, 
with similar rates of seronegative and seropositive 
patients receiving methotrexate monotherapy, triple 
therapy and biological treatment at 6 months and 24 
months (data not shown). There was a trend towards 
a higher rate of biological treatment in seronegative 
patients at the 6 month visit, as 11.8% of the seron-
egative patients (4/34) received biological treatment, 
compared with 5.1% of the seropositive patients 
(10/196, p=0.13).
dIsCussIOn
In this follow-up study of patients with early RA classified 
according to the 2010 ACR/EULAR criteria, disease 
activity after 2 years of treat-to-target therapy was similar 
in seronegative and seropositive patients, despite mark-
edly more inflammatory activity and a tendency towards 
more radiographic damage in seronegative patients at 
baseline. Treatment response was somewhat slower in 
seronegative patients and radiographic progression was 
similar in seronegative and seropositive patients. Our 
findings suggest that in patients RA classified according 
to the new criteria, seronegative RA is not a mild form 
of the disease and requires intensive treat-to-target 
therapy similar to treatment of seropositive RA.
Several studies of patients classified according to the 
1987 criteria for RA indicate that seronegative patients 
have a less severe disease course with less radiographic 
damage than seropositive patients.2–6 14 Studies have 
also shown more inflammatory activity in seropositive 
patients, with fewer patients achieving remission,4 14 15 
although evidence is somewhat conflicting.6 16 17 There 
is very limited information about the disease course of 
seronegative patients classified according to the 2010 
criteria. One recently published study in patients with 
RA fulfilling the 2010 criteria showed that patient-re-
ported outcomes including physical functioning and 
restrictions at work were similar in ACPA-positive and 
ACPA-negative patients after 4 years of follow-up.18 This 
is in line with our study where seronegative patients did 
not have a less severe disease course than seropositive 
patients, with similar rates of remission and similar 
radiographic progression over 2 years. In our study, 
there was a trend towards more radiographic damage in 
seronegative compared with seropositive patients, both 
at baseline and 24 months. The numerical differences 
may not have reached statistical significance due to the 
small number of patients in the seronegative group.
An aim for the ACR/EULAR 2010 RA classification 
criteria was to increase sensitivity for patients with 
early disease. However, the low number of seronegative 
patients included in the ARCTIC trial and, on average, 
high inflammatory activity in seronegative patients at 
baseline, indicate that the increased sensitivity may be 
confined to patients with seropositive disease.19
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Figure 1 (A–F) Disease activity measures and radiographic progression 0–24 months in seronegative and seropositive 
patients. (A–E) Margins plot over 24 months of DAS, SJC44, ultrasound power Doppler score, ultrasound grey scale Score and 
radiographic progression. Bars represent 95% CIs. (F) Cumulative probability plot of change between baseline and 24 months 
in Van der Heijde modified sharp score. DAS, Disease Activity Score; SJC, swollen joint count.
When patients were included in the ARCTIC trial, the 
ACR/EULAR 2010 classification criteria for RA were 
used. At this time, the erosion criteria had not yet been 
defined, and patients who did not otherwise fulfil the 
criteria may have been included if we had applied the 
later published erosion criteria.20 However, a recently 
published study has shown that the clinical and radio-
graphic course in ACR/EULAR 2010 negative patients 
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Table 2 Treatment response at 3 and 6 months and remission rates at 3, 6, 12 and 24 months
Seronegative
(n=34)
Seropositive
(n=196) P values
EULAR good/moderate response n (%) n (%)
   At 3 months 23 (68) 159 (81) 0.07
   At 6 months 29 (85) 161 (82) 0.66
ACR50 response
   At 3 months 10 (29) 99 (51) 0.023
   At 6 months 17 (50) 109 (56) 0.54
ACR/EULAR Boolean remission
   At 3 months 2 (6) 58 (30) 0.004
   At 6 months 11 (32) 69 (35) 0.75
   At 12 months 14 (41) 83 (42) 0.90
   At 24 months 18 (53) 94 (48) 0.59
Bold indicates p<0.05.
ACR, American Collage of Rheumatology; EULAR, European League Against Rheumatism.
under treatment was not dependent on the presence of 
erosions at diagnosis.21
Studies have shown that patients who do not respond 
significantly to treatment within 3 months have a low 
chance of attaining remission within 6 months.22 23 
According to the current EULAR recommendations 
for management of RA, treatment adjustment should 
be considered in patients with less than 50% improve-
ment in disease activity 3 months after treatment start.8 
In our study, the treatment response at 3 months 
was better in seropositive than seronegative patients, 
whereas the number of patients in remission at the end 
of the study was similar across groups. This observation 
may indicate that seronegative patients might respond 
well to treat-to-target strategies even if the initial treat-
ment response is delayed compared with seropositive 
patients.
Seronegative RA has been considered to represent 
a less severe disease subset than seropositive RA.2–6 
This assumption could possibly lead to less intensive 
treatment of seronegative patients in usual care. Our 
results highlight that both patients with seronegative 
and seropositive RA should receive intensive treat-to-
target DMARD therapy. The updated EULAR treat-
ment recommendations are more or less the same as 
the treatment protocol in the ARCTIC trial, increasing 
the generalisability of our results.
A limitation of our study is the small number of sero-
negative patients included, which limits the statistical 
power. Strengths of our study include the extensive 
data collection with radiographic and ultrasonographic 
examinations of all patients. To our knowledge, this is 
the first study to examine the disease course of sero-
negative RA in an inception cohort of DMARD-naïve 
patients classified according to the 2010 ACR/EULAR 
criteria.
In conclusion, patients with seronegative RA classified 
according to the 2010 ACR/EULAR criteria respond 
well to modern treatment strategies, but seronegative 
RA is not a mild form of the disease and requires as 
intensive treat-to-target therapy as seropositive RA.
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